| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zheng,Ming-Long | Chairman | 10.74% | ZHEN HAN INVESTMENT LTD. |
| Lu,Shan-Feng | Director | 1.06% | |
| TOP TAIWAN XI VENTURE CAPITAL CO., LTD. | Director | 0.38% | |
| Chen,Hong-Yi | Director | 0.00% | |
| Ye,Shi-Wei | Director | 7.49% | HAO CHENG INVESTMENT CO., LTD. |
| Liu,Tian-Dao | Independent Director | 0.00% | |
| Guo,Dai-Huang | Independent Director | 0.06% | |
| Wang,Xing-Wen | Independent Director | 0.00% | |
| Pan,Min-Xiong | Independent Director | 0.00% |
Change Company Name to Great Tree Pharmacy Co., Ltd.
2024/06/24
Change Capital to 2,000,000,000
2023/06/15
Change Company Name to DASHU PHARMACEUTICAL CO., LTD. (FORMER NAME: TIANJIN PHARMACEUTICAL CO., LTD.)
2022/08/23
Change Capital to 1,500,000,000
2021/07/23
Change Person in Charge to Zheng,Ming-Long
2020/12/10
Change Capital to 600,000,000
2017/09/12
Change Company Name to Great Tree Pharmacy Co., Ltd.
2014/10/03
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 17,274,254 | 16,143,701 | 14,564,645 |
| Operating cost | 12,431,678 | 11,658,104 | 10,553,517 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 4,842,576 | 4,485,597 | 4,011,128 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 4,842,576 | 4,485,597 | 4,011,128 |
| Operating expenses | 4,041,390 | 3,680,039 | 3,149,255 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 801,186 | 805,558 | 861,873 |
| Non-operating income and expenses | 45,579 | 36,263 | 20,459 |
| Net profit (loss) before tax | 846,765 | 841,821 | 882,332 |
| Income tax expense (benefits) | 166,801 | 175,337 | 181,829 |
| Net profit (loss) of ongoing business for the current period | 679,964 | 666,484 | 700,503 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 679,964 | 666,484 | 700,503 |
| Other comprehensive profit (loss), net | 12,855 | -1,118 | -279 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 692,819 | 665,366 | 700,224 |
| Net profit (loss) attributable to owners of parent company | 680,767 | 666,049 | 700,071 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -803 | 435 | 432 |
| Comprehensive profit (loss) attributable to owners of parent company | 689,612 | 665,062 | 699,860 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 3,207 | 304 | 364 |
| Basic earnings per share (yuan) | 5 | 6 | 7 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 1,138,673 | 890,331 | 1,226,695 |
| Net cash inflows (outflows) from investing activities | -881,373 | -416,526 | -465,579 |
| Net cash inflow (outflow) from financing activities | -499,079 | -795,842 | 389,097 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 9,047 | -1,638 | -273 |
| Increase (decrease) in cash and cash equivalents in the current period | -232,732 | -323,675 | 1,149,940 |
| Beginning balance of cash and cash equivalents | 2,134,734 | 2,458,409 | 1,308,469 |
| Ending balance of cash and cash equivalents | 1,902,002 | 2,134,734 | 2,458,409 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 6,489,815 | 5,975,859 | 5,745,162 |
| Non-current asset | 5,637,435 | 4,797,336 | 4,373,307 |
| Total asset | 12,127,250 | 10,773,195 | 10,118,469 |
| Current liability | 4,710,915 | 3,326,093 | 3,279,158 |
| Non-current liability | 3,768,081 | 4,095,799 | 4,214,575 |
| Total liability | 8,478,996 | 7,421,892 | 7,493,733 |
| share capital | 1,322,567 | 1,125,773 | 898,591 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,311,886 | 1,286,228 | 867,945 |
| retained earning | 956,942 | 871,920 | 835,164 |
| Other equity | 5,227 | -2,356 | -1,372 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 3,596,622 | 3,281,565 | 2,600,328 |
| Equity attributable to former owner of business combination under common control | 0 | 0 | 0 |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 51,632 | 69,738 | 24,408 |
| Total Equity | 3,648,254 | 3,351,303 | 2,624,736 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 367,800 | 451,600 | 723,900 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 27 | 29 | 28 |
